Additional safety considerations include risk of dehydration and acute kidney injury, potential worsening of diabetic retinopathy with rapid glucose improvement (particularly with semaglutide), and hypoglycemia risk when combined with insulin or sulfonylureas
Similarly, anyone experiencing unexplained fatigue, weakness, neurological symptoms (such as numbness, tingling or problems with balance), or difficulty losing weight despite appropriate lifestyle measures should consult their GP
Important Safety Considerations Semaglutide is not recommended for those with (Kommu & Whitfield, 2024) : Personal/family history of medullary thyroid carcinoma MEN2 Previous pancreatitis It can also increase the risk of hypoglycemia when used with insulin or sulfonylureas(Kommu & Whitfield, 2024)
Nonetheless, the findings have generated considerable scientific interest